ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit .RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ADMA's presentation will be on Monday, January 13, 2025, at 10:30 a.m. PT.
新澤西州拉姆西和佛羅里達州博卡拉頓，2025年1月07日（全球新聞網）-- ADMA Biologics, Inc.（納斯達克股票代碼：ADMA）（"ADMA"或"公司"），是一家專注於製造、營銷和開發特種生物製藥的端到端商業生物製藥公司，今天宣佈公司管理層將在2025年1月13日至16日在加利福尼亞州舊金山舉行的第43屆年J.P. 摩根醫療保健會議上進行演講。ADMA的演講將在2025年1月13日星期一上午10:30進行。
A live audio webcast of the call will be available under "Events & Webcasts" in the investor section of the Company's website, An archived webcast will be available on the Company's website approximately two hours after the event.
電話會議的現場音頻網絡廣播將在公司網站的投資者部分的"事件與視頻"下提供，活動結束後約兩小時將在公司網站上提供存檔網絡廣播。
About ADMA Biologics, Inc. (ADMA)
關於ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit .
ADMA Biologics是一家端到端商業生物製藥公司，專注於製造、營銷和開發特種生物製藥，用於治療面臨感染風險的免疫缺陷患者及其他某些感染性疾病風險人群。ADMA目前製造和銷售三種美國食品和藥物管理局（FDA）批准的血漿衍生生物製劑，用於治療免疫缺陷及預防某些感染性疾病：BIVIGAm（人類靜脈免疫球蛋白）用於治療原發性體液免疫缺陷（PI）；ASCENIV（人類靜脈免疫球蛋白 - slra 10%液體）用於治療PI；以及NABI-Hb（人類乙型肝炎免疫球蛋白），提供增強免疫力以對抗乙型肝炎病毒。ADMA在佛羅里達州博卡拉頓的FDA許可血漿分離和純化設施生產其免疫球蛋白產品。通過其ADMA BioCenters子公司，ADMA還作爲美國FDA批准的源血漿收集者，提供其血漿用於產品的製造。ADMA的使命是製造、營銷和開發針對特定患者群體的特種生物製劑和人類免疫球蛋白，以治療和預防某些感染性疾病，並管理因基礎免疫缺陷或其他醫療原因可能免疫受損的患者群體。ADMA擁有與其產品和產品候選者的各個方面相關的衆多美國和外國專利。欲了解更多信息，請訪問 .
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
投資者關係聯繫方式：
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
